Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUS-RFA plus Chemotherapy in Advanced Pancreatic Cancer
NCT05723107Phase 1Recruiting
- Sponsor
- NYU Langone Health
- Start
- Mar 2023
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in pancreatic ductal adenocarcinoma (PDAC), sponsored by NYU Langone Health. Primary endpoint: Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events. Started Mar 2023; status: recruiting.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05723107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723107.